NATIONAL CANCER INSTITUTE
TARGET is employing a set of advanced and complementary analysis technologies to strategically characterize alterations in both gene expression and in genomic structure (such as deletions and amplification) that are involved in five common pediatric cancers, including acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), neuroblastoma, osteosarcoma, and high-risk Wilms tumor. The goal is a comprehensive genomic and transcriptomic profile of each cancer.
These data will be annotated, archived, and processed through the Data section of this site, which will include a Biomedical Informatics Grid™ (caBIG™) – compatible, Web-based data portal. The genomic characterization data will be periodically evaluated to prioritize selections of candidate gene regions for targeted resequencing. Interpreted characterization data produced by TARGET will be made publicly available through this site, adhering to the Initiative's comprehensive patient privacy and confidentiality policies. All sequence traces will be deposited into the National Center for Biotechnology Information's trace archive as soon as they are generated.
Characterization of the TARGET project tumor specimens is being carried out at:
*The Children’s Oncology Group facilities provide tissue specimens, clinical data on patient diagnosis and treatment outcome, and statistical analyses vital to the TARGET projects.
HHS
NIH
USA
